QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.084772v1 314/2/514    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akahori, H. Articles by Takamura, T. Search for Related Content PubMed PubMed Citation Articles by Akahori, H. Articles by Takamura, T.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Tranilast Prevents the Progression of Experimental Diabetic Nephropathy through Suppression of Enhanced Extracellular Matrix Gene Expression

Department of Diabetes and Digestive Disease, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan

The present study was performed to investigate the effects of the antiallergic drug tranilast on the development of diabetic nephropathy in streptozotocin (50 mg/kg)-induced diabetic spontaneously hypertensive rats (SHR). Diabetic SHR were given standard chow or chow containing tranilast at a dose of 1400 mg/kg for 24 weeks. The effects of tranilast on urinary albumin excretion, mesangial expansion, expression of transforming growth factor- (TGF-) and type I collagen mRNAs, number of anionic sites on the glomerular basement membrane (GBM), and urinary TGF- and 8-hydroxy-2'-deoxyguanosine (8-OHdG) excretion were assessed. Tranilast did not affect the blood glucose concentration or blood pressure in diabetic SHR. Urinary albumin excretion rate and creatinine clearance were markedly increased in diabetic SHR. Tranilast treatment decreased albuminuria and hyperfiltration. Tranilast inhibited the diabetes-induced expansion of mesangial and tuft areas, as well as the increase in urinary TGF- and 8-OHdG excretion, loss of anionic sites of GBM, and overexpression of TGF- as determined immunohistochemically. The levels of TGF- and type I collagen mRNA expression were increased in the renal cortex in untreated diabetic SHR at 24 weeks, as determined by real-time quantitative polymerase chain reaction. Tranilast treatment inhibited the up-regulation of TGF- and type I collagen mRNA expression by 65 and 36%, respectively, in diabetic SHR. In conclusion, tranilast decreased albuminuria by suppressing glomerular hyperfiltration, mesangial expansion, and loss of the charge barrier via regulation of extracellular matrix gene expression and oxidative stress. Tranilast may be clinically useful in the treatment of diabetic nephropathy.

Address correspondence to: Dr. Toshinari Takamura, Department of Diabetes and Digestive Disease, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa, Japan 920-8641. E-mail: tt{at}medf.m.kanazawa-u.ac.jp

This article has been cited by other articles:

				P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]

				D. Gong, J. Lu, X. Chen, S. Y. Choong, S. Zhang, Y.-K. Chan, S. Glyn-Jones, G. D. Gamble, A. R. J. Phillips, and G. J. S. Cooper Molecular Changes Evoked by Triethylenetetramine Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic Rats Mol. Pharmacol., December 1, 2006; 70(6): 2045 - 2051. [Abstract] [Full Text] [PDF]

				J. Soma, K. Sato, H. Saito, and Y. Tsuchiya Effect of tranilast in early-stage diabetic nephropathy Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2795 - 2799. [Abstract] [Full Text] [PDF]